drugset / Trial / NCT00262483
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
Non-randomizedSingle-groupOpen-label
Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.
Timeline
- Start
- 2005-12
- Primary completion
- —
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Subject | Ribavirin | Small molecule | — | — |
| Subject | Telaprevir | Small molecule | — | — |